Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan inhalations in COVID-19 pneumonia
NCT04380376Phase 2Unknown
- Sponsor
- Research Institute of Pulmonology
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) and viral pneumonia comparing Melphalan inhalations with Standard of care group (2 arms). Primary endpoints: COVID Ordinal Outcomes Scale at 28 days, Percentage of patients with Clinical Recovery at 28 days and 1 more. Status: unknown.
02
Drugs
melphalan
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on NCT04380376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380376.